MNKD - MannKind Corporation

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0400
-0.0500 (-4.59%)
At close: 4:00PM EDT

1.0400 0.00 (0.00%)
After hours: 5:53PM EDT

Stock chart is not supported by your current browser
Previous Close1.0900
Open1.1000
Bid1.0400 x 21500
Ask1.1200 x 34100
Day's Range1.0300 - 1.1000
52 Week Range0.9400 - 3.0400
Volume4,294,763
Avg. Volume2,047,962
Market Cap195.294M
Beta (3Y Monthly)2.19
PE Ratio (TTM)N/A
EPS (TTM)-0.4450
Earnings DateAug 6, 2018 - Aug 10, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • GlobeNewswire3 days ago

    MannKind Partners with GoodRx to Help Raise Awareness on Reducing Out of Pocket Insulin Cost for Patients

    WESTLAKE VILLAGE, Calif., July 15, 2019 (GLOBE NEWSWIRE) --  MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, today announced that it has partnered with GoodRx to help raise awareness on ways patients can save money on their mealtime insulin.

  • GlobeNewswire7 days ago

    MannKind Expands Commercial Scale Manufacturing Capabilities for High-Potency Molecules

    MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, announced that it has completed construction of a new high-potency manufacturing suite in its Danbury Connecticut facility.  This expansion provides the Company with the capability to produce dry powder formulations of highly potent active ingredients, such as epinephrine, on a commercial scale, in alignment with MannKind's strategic partnerships. The new suite will house bulk powder formulation and fill/pack operations for high-potency powders and adds to MannKind's extensive commercial manufacturing capability, which includes inhalation devices, large-scale compounding, particle formation, tangential flow filtration, cryogranulation, and high capacity (300 kg/day) lyophilization.

  • What Kind Of Shareholders Own MannKind Corporation (NASDAQ:MNKD)?
    Simply Wall St.9 days ago

    What Kind Of Shareholders Own MannKind Corporation (NASDAQ:MNKD)?

    If you want to know who really controls MannKind Corporation (NASDAQ:MNKD), then you'll have to look at the makeup of...

  • Zacks Small Cap Researchlast month

    MNKD: ADA Presentations: Positive Pediatric Data Lends Support for Anticipated Pivotal Study. Adult Data Highlights Benefits, Safety of Higher Doses

    New data from three different studies of Afrezza was announced at the American Diabetes Association’s 79th Scientific Sessions (June 7 – 11) in San Francisco. This includes safety and PK data from MannKind’s (MNKD) ongoing pediatric study. This pediatric data, which comes from the first of three age-based patient cohorts is particularly insightful as it provides one of the initial meaningful glimpses of utility of Afrezza in younger populations.

  • GlobeNewswirelast month

    MannKind to Present at the JMP Securities Life Sciences Conference

    WESTLAKE VILLAGE, Calif., June 12, 2019 -- MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for.

  • GlobeNewswirelast month

    MannKind Presents Positive Afrezza® Clinical Data from Three Studies at ADA 79th Scientific Sessions

    MannKind Corporation (MNKD) announced that new data from three different studies of Afrezza® (insulin human) Inhalation Powder were released at the American Diabetes Association’s 79th Scientific Sessions, being held June 7-11, in San Francisco, California. MannKind will present a poster with initial information from its ongoing study of Safety and Pharmacokinetics of Technosphere Insulin (Afrezza) in Pediatric Patients ¹ on Monday, June 10.  This study is the first step in preparation for a phase 3 safety and efficacy study.

  • GlobeNewswirelast month

    Afrezza® (insulin human) Inhalation Powder Approved in Brazil

    Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. WESTLAKE VILLAGE, Calif. and BELO HORIZONTE, Brazil, June 03, 2019 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) and BIOMM SA (BIOM3.SA) today announced that Afrezza® (insulin human) Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency (ANVISA).

  • 2 Healthcare Stocks That Could Double Your Money
    Motley Fool2 months ago

    2 Healthcare Stocks That Could Double Your Money

    Should you be as excited as the analysts who think these stocks are two-baggers in the making?

  • Benzinga2 months ago

    The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...

  • GlobeNewswire2 months ago

    MannKind Announces Afrezza® Distribution Agreement in Australia

    MannKind Corporation (MNKD) today announced that it has entered into an exclusive marketing and distribution agreement with the AMSL Diabetes division of Australasian Medical & Scientific Ltd. for the commercialization of Afrezza® (insulin human) Inhalation Powder in Australia. "We are excited to partner with AMSL Diabetes to accelerate patients’ access to Afrezza in Australia," said Michael Castagna, Chief Executive Officer of MannKind Corporation.

  • Why MannKind Is Up Big Today
    Motley Fool2 months ago

    Why MannKind Is Up Big Today

    Shares rise after the company receives some praise from a pair of Wall Street analysts.

  • Zacks Small Cap Research2 months ago

    MNKD: Product Sales Up 49% on 71% Growth in Demand. Product Margin Continues to Expand

    MannKind (MNKD) reported financial results for their first quarter ending March 31st and provided a business update. As it relates to the financials, total revenue was $17.4M, which included $5.1M in product sales and $12.4M in collaboration revenue.

  • MannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    MannKind Corporation (MNKD) Q1 2019 Earnings Call Transcript

    MNKD earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of MNKD earnings conference call or presentation 7-May-19 1:00pm GMT

    Q1 2019 MannKind Corp Earnings Call

  • Associated Press2 months ago

    MannKind: 1Q Earnings Snapshot

    The Westlake Village, California-based company said it had a loss of 8 cents per share. The results matched Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • GlobeNewswire2 months ago

    MannKind Corporation Reports 2019 First Quarter Financial Results

    1Q 2019 Total Revenues of $17.4 million 1Q 2019 Afrezza Net Revenue was $5.1 million; +49% vs. 1Q 2018 1Q 2019 Collaborations and Services Revenue was $12.4 million 1Q 2019 net.

  • United Therapeutics (UTHR) Down Despite Q1 Earnings Beat
    Zacks3 months ago

    United Therapeutics (UTHR) Down Despite Q1 Earnings Beat

    United Therapeutics (UTHR) beats estimates on both fronts in the first quarter. However, earnings and revenues decline year over year.

  • GlobeNewswire3 months ago

    MannKind Corporation to Hold 2019 First Quarter Financial Results Conference Call on May 7, 2019

    WESTLAKE VILLAGE, Calif., April 30, 2019 -- MannKind Corporation (Nasdaq:MNKD) will release its 2019 first quarter financial results on Tuesday, May 7, 2019 and its management.

  • GlobeNewswire3 months ago

    MannKind Presents Scientific Data at 28th Annual Scientific and Clinical Congress of the American Association of Clinical Endocrinologists (AACE 2019)

    WESTLAKE VILLAGE, Calif., April 25, 2019 -- MannKind Corporation (Nasdaq:MNKD) today announced additional data supporting the distinct clinical profile of Afrezza will be.

  • GlobeNewswire4 months ago

    MannKind to Present at the H.C. Wainwright Global Life Sciences Conference

    If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link (www.hcwevents.com ) to register for the conference.  Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company. The presentation will be webcast live.  To access the webcast, please visit www.hcwevents.com.  Interested parties can also access a link to the live webcast of the presentation from the News & Events section of the Company's website at http://www.mannkindcorp.com.  The webcast replay will remain available for 14 days following the live presentation.

  • GlobeNewswire4 months ago

    MannKind Receives $12.5 Million Milestone Payment from United Therapeutics

    MannKind Corporation (MNKD) today announced that it achieved the first of several specified development milestones under its licensing and collaboration agreement with United Therapeutics for the development and commercialization of a dry powder formulation of treprostinil.  Treprostinil Technosphere (“TreT”) is an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension.  Pursuant to the agreement, MannKind is eligible to earn additional payments up to $37.5 million upon the achievement of other defined development milestones.  MannKind will also be entitled to receive low double-digit royalties on net sales of TreT.

  • Analysts Give Positive Recommendations to MannKind in March
    Market Realist4 months ago

    Analysts Give Positive Recommendations to MannKind in March

    How These Biotechnology Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target price Wall Street analysts expect upside potential of 75.00% for MannKind (MNKD) based on the company’s closing price on March

  • MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?
    Market Realist4 months ago

    MannKind or Akebia: Who’s Expected to Report Faster EPS Growth?

    MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Financial performance In the fourth quarter, MannKind Corporation (MNKD) reported revenue of $16.03 million, a YoY (year-over-year) rise of 253.91%. According

  • MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?
    Market Realist4 months ago

    MNKD or AKBA: Which Is Expected to Report Faster Revenue Growth?

    MannKind or Akebia: Which Is a Better Biotech Pick This Month?(Continued from Prior Part)Growth trendsIn its fourth-quarter earnings investor presentation, MannKind Corporation (MNKD) announced that Afrezza had seen fiscal 2018 net sales of $17.3

  • What Analysts Are Recommending for MannKind and Akebia in March
    Market Realist4 months ago

    What Analysts Are Recommending for MannKind and Akebia in March

    MannKind or Akebia: Which Is a Better Biotech Pick This Month?Share price movementsOn March 12, MannKind Corporation (MNKD) closed at $2.09, 8.29% higher than its previous closing price, 122.34% higher than its 52-week low of $0.94, and 31.25% lower